3:37 PM
 | 
Sep 12, 2017
 |  BC Extra  |  Clinical News

Sage falls on Phase III data for seizure indication

Sage Therapeutics Inc. (NASDAQ:SAGE) lost $12.12 (14%) to $76.40 on Tuesday after it said brexanolone (SAGE-547) missed the primary endpoint in the Phase III STATUS trial to treat super-refractory status epilepticus (SRSE). SRSE is a persistent state of seizure that does...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >